Predilife
Predilife S.A. is a French publicly listed health-technology company that delivers AI-powered, teleconsultation-based predictive health assessments for breast cancer and other serious illnesses, sold primarily to large enterprises and through insurance broker and mutual-fund channels across Europe.
- Company typePublic
- Founded2018
- HeadquartersVillejuif, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Predilife does
Predilife S.A. is a French publicly listed health-technology company that develops AI-driven predictive health assessments combining polygenic risk scoring, mammographic image analysis, and clinical data to estimate individual risk of serious illnesses — primarily breast cancer, but also prostate, colorectal, and lung cancers, melanoma, and cardiovascular disease. Its core products are delivered via a secure teleconsultation platform and include MammoRisk (breast cancer risk assessment for women aged 40 and above), Bilan prédictif multi-pathologies (a multi-pathology predictive check-up covering breast, prostate, colorectal, and lung cancers plus melanoma and cardiovascular disease for men and women aged 40 and above), Bilan de santé (a general employee health assessment covering overall health, mental health, vaccination status, and chronic-disease risk factors), and the DenSeeMammo computer-vision tool for breast-density evaluation. The company's algorithms are protected by a patent granted in May 2024 for its AI risk-prediction method, and its medical-device software holds CE marking in the EU, ANSM registration in France, and MHRA registration in the UK, with FDA engagement underway for the DenSeeRisk device (feedback received March 2025).
The technology stack rests on two AI modalities: a structured-data risk engine that combines genetic markers (SNPs/PRS), family history, mammographic density, and clinical variables, and a computer-vision model that classifies breast density from mammography images. Predictive models have been trained and validated through collaborations with academic partners including AP-HP Sorbonne Université Tenon (Paris), University of Geneva, Institut Curie, and access to UK Biobank data; a study of 311 women showed strong correlation between the DenSeeMammo AI's breast-density assessment and radiologist evaluation. Genetic analysis is performed in partnership with Eurofins and other specialised laboratories.
The business is monetised primarily through enterprise subscriptions sold to large corporations for employee wellness programs and through insurance broker and mutual fund channels — including Mercer, Roederer, DIOT-SIACI, APICIL, and Groupe Mutuel — that distribute the assessments to corporate and policyholder clients. Named enterprise customers span insurance (Allianz France, Mercer France), retail and consumer goods (Lactalis, Marionnaud, Groupe Rocher, Socamaine E.Leclerc, Cojean), media (TF1), public sector (Unédic), finance (In Extenso Finance), and infrastructure (Colas Rail). Pricing is not publicly disclosed but is positioned at up to five times lower cost than traditional health check-ups. The company is listed on Euronext (ticker ALPRE), is headquartered in Villejuif with a secondary office in Saint-Cloud, operates with 11–50 employees, and is active in France, the UK, Switzerland, Italy, and the Middle East.
Predilife firmographics
Firmographics- Name
- Predilife
- Legal name
- Predilife S.A.
- Website
- https://predilife.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Predilife S.A. is a French publicly listed health-technology company that delivers AI-powered, teleconsultation-based predictive health assessments for breast cancer and other serious illnesses, sold primarily to large enterprises and through insurance broker and mutual-fund channels across Europe.
- Ownership category
- akta.pro rank
Predilife industry classification
Industry- Product category
- Predictive Medicine Software
- NAICS
- Software Publishers (5132)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Population Genomics & Preventive Precision Health Programs (HLAAANAL)
- akta.pro secondary industries
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE), Risk Stratification & Predictive Modeling (utilization, cost, readmission) (HLACAHAB), Medical Imaging AI (HDAAAEAH), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)
Keywords
Where Predilife is headquartered
LocationHeadquarters
- HQ city
- Villejuif
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Predilife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Predictive Health Assessment Subscriptions: Subscription-based predictive health assessments offered to enterprises for their employees and to insurance partners for distribution to their members. Provides recurring revenue through annual or multi-year subscription contracts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise Employee Health Assessment |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Predilife product offering
Product offeringCore offering
Predilife sells AI-powered predictive health assessment software and associated digital check-up services that estimate individual risk for breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, and cardiovascular disease. The offering combines clinical questionnaires, genetic analysis (saliva sample), mammographic imaging, and proprietary AI algorithms to generate personalized risk profiles and screening recommendations, delivered via teleconsultation to enterprises, insurers, healthcare institutions, and individual consumers.
Product overview
Predilife is a pioneer in predictive medicine in France, offering a portfolio of three digital preventive health check-ups delivered via a secure teleconsultation platform. The core offerings are: MammoRisk (breast cancer predictive assessment for women 40+), the Multi-pathology Predictive Check-Up (covering breast, prostate, colorectal, lung cancers, melanoma, and cardiovascular diseases for men and women 40+), and a general Health Check-Up (for all employees). These predictive assessments combine traditional medical techniques with AI algorithms and Big Data analytics to establish personalized risk profiles and screening recommendations. The MammoRisk software is the company's primary medical device, with the DenSeeMammo AI component used for breast density evaluation.
Differentiator
Problem solved
Functional benefit
Brands
- MammoRisk: Breast cancer predictive check-up assessment for women from 40 years old, combining clinical data, mammography, and genetic analysis.
- Bilan prédictif multi-pathologies
- Bilan prédictif du cancer du sein
Products and services
- MammoRisk Predictive check-up for breast cancer risk assessment targeting women aged 40 and above. Combines AI algorithms with clinical data, genetic analysis from a saliva sample, mammographic density, and family history to estimate 5-year breast cancer risk and provide personalized screening recommendations. Sold to enterprises for employee benefit programs, through insurance brokers and mutuals, via medical institution referrals, and directly to consumers via teleconsultation.
- Bilan prédictif du cancer du sein (Predictive Breast Cancer Check-Up) Standalone predictive breast cancer check-up for women aged 40 and above that estimates individual breast cancer risk and delivers personalized follow-up recommendations. Delivered via teleconsultation and available through enterprise, insurance, and direct consumer channels.
- Bilan prédictif multi-pathologies (Multi-Pathology Predictive Check-Up) Comprehensive predictive health assessment for men and women aged 40 and above covering breast cancer, prostate cancer, colorectal cancer, lung cancer, melanoma, and cardiovascular disease. Combines teleconsultation, medical questionnaire, biological and genetic analyses (saliva sample) to establish personalized risk profiles and adapted medical follow-up recommendations.
- Bilan de santé (Employee Health Check-Up) General predictive health check-up offered to all employees (not limited by age or gender) covering overall health status, mental health, vaccination status, and risk factors for chronic diseases. Provides personalized recommendations for proactive health management and is sold as part of corporate wellness programs.
- DenSeeMammo AI-powered medical device software that automatically evaluates breast density from mammography images, demonstrating strong correlation with radiologist assessments in clinical validation. Used in clinical practice for breast cancer screening and as the imaging analysis component of the broader MammoRisk offering.
- ColonRisk Standalone medical device software for colorectal cancer risk estimation, part of Predilife's suite of pathology-specific risk assessment products distributed to individuals and corporate customers.
- MelanoRisk Standalone medical device software for melanoma risk estimation, part of Predilife's pathology-specific risk assessment product line.
- CardiRisk Standalone medical device software for cardiovascular disease risk estimation, launched as part of Predilife's expansion into multi-pathology prediction.
- LungRisk Standalone medical device software for lung cancer risk estimation, part of Predilife's pathology-specific risk assessment product line.
Quantifiable outcome
- Predictive health assessments priced up to 5x lower than traditional health check-up programs
- +2 more outcomes
Companies that use Predilife
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles4 records
Predilife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Predilife partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- MercercoreStrategic partnership for B2B offerings of predictive health assessments to corporate clients. Mercer, a leading HR and benefits consulting firm, integrates Predilife's solutions into their corporate wellness offerings.
- PointGyncoreMedical centers specializing in women's health that offer Predilife's predictive health assessments to their patients, particularly for breast cancer risk assessment.
- Hôpitaux du LémancoreRegional hospital institution that serves as an institutional partner for predictive health services and medical referrals.
- Institut Français du SeincoreFrench breast health institute providing institutional partnership for breast cancer risk assessment services.
- Institut du Sein PariscoreParis-based breast health institute partner for predictive breast cancer assessment services.
- American Hospital of PariscorePrestigious international hospital in Paris providing institutional partnership for predictive health services.
- Institut du Sein Henri HartmanncoreRenowned breast health center in Paris, providing referrals and integration for breast cancer risk assessments.
- France SurgeryminorMedical tourism and intermediary services partner for international B2B referrals.
- RoederercoreInsurance broker partnership for distributing predictive health assessments to corporate clients.
- DIOT-SIACIcoreInsurance broker partnership for distributing predictive health assessments through their corporate client network.
- APICILcoreInsurance group partnership for offering predictive health assessments to member companies.
- Groupe MutuelcoreSwiss insurance group partnership for distribution of predictive health services.
- French Tech Grand ParisminorMembership in French Tech community providing ecosystem support and visibility.
- French CareminorMembership in healthcare innovation community for networking and partnerships.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Predilife competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat6 records
Customer concentration
Predilife social profiles
Digital presencePredilife compliance and trust
Trust signalCompliance4 records
Predilife financial estimates
Financial estimateRevenue estimate
Valuation estimate
Predilife leadership team
Management profileNumber of profiles
Profiles1 record
Predilife subsidiaries and ownership
Company hierarchySubsidiaries2 records
Predilife funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Predilife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Predilife
What does Predilife do?
Predilife sells AI-powered predictive health assessment software and associated digital check-up services that estimate individual risk for breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, and cardiovascular disease. The offering combines clinical questionnaires, genetic analysis (saliva sample), mammographic imaging, and proprietary AI algorithms to generate personalized risk profiles and screening recommendations, delivered via teleconsultation to enterprises, insurers, healthcare institutions, and individual consumers.
Is Predilife a public or private company?
Predilife is a public company. It is classified as public and is currently operating.
When was Predilife founded?
Predilife was founded in 2018. It employs 11 to 50 people.
Where is Predilife based?
Predilife is headquartered in Villejuif, France, in the Europe region.
How does Predilife make money?
One revenue line is on record: predictive Health Assessment Subscriptions.
Does Predilife have an API?
No public API is recorded for Predilife.
What industry is Predilife in?
Predilife's product category is Predictive Medicine Software. Its primary akta.pro industry code is HLAAANAL, Population Genomics & Preventive Precision Health Programs, with a secondary code of HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics. Its NAICS code is 5132 and its SIC code is 2835.